X0609 4 2026-06-03 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001270354 PERSKY MARLA false C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 1 0 0 0 1 Common Stock 2026-06-03 4 S 0 15500 5.8989 D 126500 D Common Stock 2026-06-04 4 A 0 24193 0 A 150693 D Common Stock 6370 I By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000 Stock Option (Right to Buy) 6.15 2026-06-04 4 A 0 32996 6.15 A 2036-06-04 Common Stock 32996 32996 D The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.810 to $5.960, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. /s/ Beth Hecht, Attorney-in-Fact 2026-06-05